HCA Healthcare Q2 EPS Estimate Boosted by Zacks Research

robot
Abstract generation in progress

Zacks Research has increased its Q2 2026 EPS estimate for HCA Healthcare to $7.27, up from $7.21, and also adjusted several longer-term forecasts, including FY2026 EPS to $29.82. Despite some cuts to future period estimates, the overall analyst sentiment remains positive with a “Moderate Buy” rating and an average price target of $517.82, suggesting significant upside potential. HCA Healthcare recently reported Q1 earnings that slightly missed EPS estimates but beat revenue expectations, and declared a quarterly dividend of $0.78 per share.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin